Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

The primary purpose of this trial is to determine whether adding new drugs to the standard initial cancer treatments for breast cancer increases the probability there there will be no residual disease (cancer cells left after many attempts to remove the cancer), compared to the initial cancer treatment alone. The intervention includes different drugs to determine which study drugs might result in better outcomes than standard treatment.

Are you Eligible? (Inclusion Criteria)

• To be eligible for this trial patients must:
• have breast cancer and cannot already have had chemotherapy.
• be at least 18 years of age.
• not be pregnant and not become pregnant while on the trial.